Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | IL2 | P60568 | 4/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813073 | 0.96 | IL2 (0.47) | L3MBTL1IL2NPC1ALDH1A1PKM | |
| SCHEMBL438956 | 0.92 | STIM1 (0.50) | L3MBTL1IL2RXFP1NPC1ALDH1A1 | |
| SCHEMBL449981 | 0.90 | IL2 (0.46) | IL2TYK2NPC1ALDH1A1PKM | |
| SCHEMBL437873 | 0.87 | SMN1; SMN2 (0.55) | RXFP1NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2817899 | 0.84 | IL2 (0.61) | IL2ABL1 | |
| SCHEMBL4767857 | 0.84 | IL2 (0.61) | IL2TYK2JAK2JAK1RAB9A | |
| SCHEMBL437850 | 0.83 | NPC1 (0.43) | IL2NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3813349 | 0.81 | IL2 (0.54) | IL2TYK2JAK2JAK1NPC1 | |
| SCHEMBL2311150 | 0.80 | IL2 (0.43) | IL2NPC1ALDH1A1PKMTSHR | |
| SCHEMBL2813597 | 0.80 | IL2 (0.48) | IL2TYK2JAK2JAK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | claimed |
| EP-2182808-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20170183374-A1 | Methods of Constructing and Screening Libraries of Peptide Structures | PHYLOGICA LIMITED (AU) | 2017-06-29 | — | — | US | disclosed |
| US-9567373-B2 | Methods of constructing and screening libraries of peptide structures | PHYLOGICA LIMITED (AU) | 2017-02-14 | — | — | US | disclosed |
| EP-1987178-B1 | METHOD OF CONSTRUCTING AND SCREENING LIBRARIES OF PEPTIDE STRUCTURES | PHYLOGICA LTD (AU) | 2015-03-25 | — | — | EP | disclosed |
| US-8802634-B2 | CD40-L Inhibitory Peptides | PHYLOGICA LIMITED (AU) | 2014-08-12 | — | — | US | disclosed |
| US-20140128268-A1 | Methods of Constructing and Screening Libraries of Peptide Structures | PHYLOGICA LIMITED (AU) | 2014-05-08 | — | — | US | disclosed |
| US-8575070-B2 | Methods of constructing and screening libraries of peptide structures | PHYLOGICA LIMITED (AU) | 2013-11-05 | — | — | US | disclosed |
| US-20130266605-A1 | PEPTIDE INHIBITORS OF CD40L SIGNALING AND USES THEREFOR | PHYLOGICA LIMITED (AU) | 2013-10-10 | — | — | US | disclosed |
| EP-2616480-A1 | PEPTIDE INHIBITORS OF CD40L SIGNALING AND USES THEREFOR | Phylogica Limited (AU) | 2013-07-24 | — | — | EP | disclosed |
| US-20120065134-A1 | CD40-L INHIBITORY PHYLOMER PEPTIDES | PHYLOGICA LIMITED (AU) | 2012-03-15 | — | — | US | disclosed |
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | disclosed |
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (MA) | 2012-03-15 | — | — | US | disclosed |
| EP-2310405-A1 | PEPTIDE INHIBITORS OF CD40L SIGNALING AND USES THEREFOR | Phylogica Limited (AU) | 2011-04-20 | — | — | EP | disclosed |
| EP-2182808-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010003193-A1 | PEPTIDE INHIBITORS OF CD40L SIGNALING AND USES THEREFOR | PHYLOGICA LIMITED (AU) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017819-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080081768-A1 | Methods of constructing and screening libraries of peptide structures | PHYLOGICA LIMITED (AU) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064121-A1 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | IL5, CXCR3, TSLP | L3MBTL1 4278/4885IL2 24/4885TYK2 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.